Document is current
Any future updates will be listed below
-
Authors
Bonnet, Fabrice
Doumbia, Adama
Machault, Vanessa
Ello, Frederic Nogbou
Bellecave, Pantxika
Akpovo, Corine Bernice
Sidibe, Baba Toumany
Fernandez, Laura
Kouamé, Antoine
Adjogoua, Edgard
Dosso, Mireille
Niangoran, Serge
Journot, Valérie
Eholié, Serge Paul
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04466241 at ClinicalTrials.govDocuments that mention this clinical trial
Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial
https://doi.org/10.1038/s41598-024-72449-1
-
Funding
Funding for this research was provided by:
ANRS/MIE (ECTZ 143960)
- License Information
-
More Information
Article History
Received: 24 October 2023
Accepted: 6 September 2024
First Online: 23 October 2024
Competing interests
: Fabrice Bonnet has received consulting honoraria, research grants, or both from Gilead Sciences, MSD, and ViiV Healthcare, outside the submitted work. Other authors have nothing to disclose. The other authors declare no competing interests.
: The trial was approved by the institutional national ethics committee (Comité National d’Ethique de la Vie et de la Santé (CNEVS), July 27, 2020) and was conducted in accordance with the 1964 Helsinki Declaration and the French and Ivorian regulations on clinical trials. We obtained written informed consent from all patients.
